Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors

Activating mutations in RAS family proteins are found in ~25% of all human cancers. Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten RAS (KRAS) being the most frequently mutated isoform. Historically, KRAS has been acknowledged as “undruggable”, largely b...

Descripción completa

Detalles Bibliográficos
Autores principales: Indini, Alice, Rijavec, Erika, Ghidini, Michele, Cortellini, Alessio, Grossi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147792/
https://www.ncbi.nlm.nih.gov/pubmed/34064352
http://dx.doi.org/10.3390/pharmaceutics13050653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147792/
https://www.ncbi.nlm.nih.gov/pubmed/34064352
http://dx.doi.org/10.3390/pharmaceutics13050653

Ejemplares similares